Benjamin Tomlinson, MD
- Program Director, Hematology and Oncology, UH Cleveland Medical Center
- Assistant Professor, CWRU School of Medicine
- Specialty: Hematology and Oncology
-
Location:UH Seidman Cancer Center at UH St. John Medical Center
29325 Health Campus Dr
Westlake, OH 44145
- Call: 440-617-4700
Biography: Benjamin Tomlinson, MD
Expertise
Certifications & Memberships
- Medical Oncology - American Board of Internal Medicine
- Hematology - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - University Of California At Davis Comprehensive Cancer Center (2012 - 2015)
Residency | Internal Medicine
Internal Medicine - Uc Davis Medical Center (2009 - 2012)
Medical Education
Case Western Reserve University School Of Medicine (2009)
Undergraduate
Case Western Reserve University (2005)
About
Benjamin K. N. Tomlinson, MD, is a hematologist-oncologist at University Hospitals Seidman Cancer Center and an Assistant Professor of Medicine at Case Western Reserve University School of Medicine. He is board-certified in Internal Medicine, Hematology and Medical Oncology and subspecializes in malignant hematology, specifically acute leukemias and myeloid neoplasms.
Dr. Tomlinson started as faculty at the UH Seidman Cancer Center after completing his internal medicine and fellowship training at UC Davis in Sacrament California. He is a member of the malignant hematology group and also follows patients through stem cell transplants. He also serves as program director for the hematology and oncology fellowship program sponsored by University Hospitals.
Dr. Tomlinson completed his undergraduate and medical degrees at Case Western Reserve University. He maintains board certification in both Hematology and Oncology and is an active member of the American Society of Clinical Oncology, American Society of Hematology, and the American Society of Transplant and Cellular Therapy.
Dr. Tomlinson’s research interests include clinical outcomes of patients with myeloid neoplasms, novel diagnostics such as measurable residual disease, and optimizing therapeutic effects while minimizing toxicity in the treatment of both myelodysplastic syndromes and acute leukemias.
Research & Publications
Research Links
PubMed
View Research
Featured Videos
Watch to find out more about this University Hospitals provider.